Angiosarcoma of the scalp treated with OK‐432 and rIL‐2

Miura, Hiroyuki; Inui, Sigeki; Hasebe, N.; Itami, Satoshi; Yoshikawa, Kunihiko

doi:10.1046/j.1365-4362.2002.01356_1.x

Cited by 6 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…docetaxel) and immunotherapy (e.g. IL‐2 and picibanil) are available, alone or in combination . However, complete remission is rare and patients frequently achieve disease stabilization in the presence of residual angiosarcoma masses .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survivin: A novel marker and potential therapeutic target for human angiosarcoma

et al. 2017

View full text Add to dashboard Cite

Human angiosarcoma is a rare malignant vascular tumor associated with extremely poor clinical outcome and generally arising in skin of the head and neck region. However, little is known about the molecular pathogeneses and useful immunohistochemical markers of angiosarcoma. To investigate the mechanisms of angiosarcoma progression, we collected 85 cases of human angiosarcoma specimens with clinical records and analyzed ISO‐HAS‐B patient‐derived angiosarcoma cells. As control subjects, 54 cases of hemangioma and 34 of pyogenic granuloma were collected. Remarkably, consistent with our recent observations regarding the involvement of survivin expression following Hippo pathway inactivation in the neoplastic proliferation of murine hemangioendothelioma cells and human infantile hemangioma, nuclear survivin expression was observed in all cases of angiosarcoma but not in hemangiomas and pyogenic granulomas, and the Hippo pathway was inactivated in 90.3% of yes‐associated protein (YAP) ‐positive angiosarcoma cases. However, survivin expression modes and YAP localization (Hippo pathway activation modes) were not correlated with survival. In addition, we confirmed that survivin small interference RNA (siRNA) transfection and YM155, an anti‐survivin drug, elicited decreased nuclear survivin expression and cell proliferation in ISO‐HAS‐B cells which expressed survivin consistently. Conclusively, these findings support the importance of survivin as a good marker and critical regulator of cellular proliferation for human angiosarcoma and YM155 as a potential therapeutic agent.

show abstract

Section: Discussionmentioning

confidence: 99%

“…IL-2 and picibanil) are available, alone or in combination. (22)(23)(24) However, complete remission is rare and patients frequently achieve disease stabilization in the presence of residual angiosarcoma masses. (25) Several potential theories relating to the development of angiosarcomas have been proposed and discussed.…”

Section: Discussionmentioning

confidence: 99%

Survivin: A novel marker and potential therapeutic target for human angiosarcoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…15 The use of sclerosing agent OK-432 in combination with interleukin-2 has been reported in a single case, with regression of the lesion. 16 Docetaxel was reported to be efficient in the treatment of cutaneous angiosarcoma. In a series of nine patients with cutaneous angiosarcoma, six presented major responses, including four complete responses.…”

Section: Discussionmentioning

confidence: 99%

“…The use of angiostatic chemotherapy has been reported in a small series, but with promising results 15 . The use of sclerosing agent OK‐432 in combination with interleukin‐2 has been reported in a single case, with regression of the lesion 16 . Docetaxel was reported to be efficient in the treatment of cutaneous angiosarcoma.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous angiosarcoma of the head and neck: Report of 23 cases from a single institution

Köhler

Neves

Brechtbühl

et al. 2008

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“…The most common metastatic sites are lung, liver, lymph nodes, bone and skin. Although treatments including surgical excision, radiation, polychemotherapy, OK432 and recombinant interleukin‐2 3–5 are performed alone or in combination for metastatic angiosarcoma, the prognosis remains desperately poor. We report a patient with pleural and lung metastasis of angiosarcoma of the head treated with docetaxel who showed a partial response.…”

mentioning

confidence: 99%

Weekly low-dose docetaxel in the treatment of lung metastases from angiosarcoma of the head

et al. 2005

View full text Add to dashboard Cite

Angiosarcoma of the scalp treated with OK‐432 and rIL‐2

Cited by 6 publications

References 17 publications

Survivin: A novel marker and potential therapeutic target for human angiosarcoma

Survivin: A novel marker and potential therapeutic target for human angiosarcoma

Cutaneous angiosarcoma of the head and neck: Report of 23 cases from a single institution

Weekly low-dose docetaxel in the treatment of lung metastases from angiosarcoma of the head

Contact Info

Product

Resources

About